Tempest Therapeutics Inc (TPST) Stock Price, Quote & News

Company Profile

Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its clinical-stage lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma; and TPST-1495, a small-molecule dual antagonist of the EP2 and EP4 receptors of prostaglandin E2 for treating various cancers. The comp...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 798 8589

Website: www.tempesttx.com

Address:

2000 Sierra Point Parkway, Suite 400, Brisbane, United States

gscdefense Oct. 5 at 12:59 AM

$TPST So we just went from 5747 on Webull popularity ranking to 439. There was only one comment today.

1 · Reply

gainsareus Oct. 5 at 12:22 AM

$TPST probably one of the most intelligent boards I’ve seen. Is it because bio requires higher intelligence or you’ll just know where the winners are🤔

1 · Reply

josegodoy Oct. 4 at 11:29 PM

$TPST don’t let them fool you!! Chart #1 1) the 50 day line (blue line) is bullish property (bulls thrive above it) 2) black vertical line (a MARKED change in behavior) 2a) look to the left of the vertical line: - do you see respect or disrespect?…..bears trample over/under/in between and any other way they felt like 2b) look to the right of the line - GREEN RECTANGLE (especially): bears run up-to the 50 with some very nice/large red candles but… - on decreasing volume and… - a HARD stop at the 50 Note: in general, just look from left to right and see the dips (below the 50) get more and more shallow (until finally, they can’t breach it anymore) Chart #2 - Failure of a bearish formation (red neckline) is bullish by definition/default and vice versa (green neckline) - are the bulls gonna represent?…. I guess it don’t really matter (if buyout (in all likelihood (but still you never really know))) 😂

1 · Reply

GreylockSec Oct. 4 at 9:30 PM

$TPST ...Yes, it appears that the original show and content was originally aired by Big Biz on 1/21/25 --> https://www.youtube.com/watch?v=mFEib_IZgA4 whereas the newest airing from 9/15/25 has different but related portions from the original program which was likely much, much longer & trimmed to fit. Both medical doctors (Dr. Yarchoan & Dr. Greten) are in both segments; and Dr. Burdette has long departed since May anyway. Going deeper, Both Brady and his host are wearing the exact same clothes (in the January and in September 25 clips). Dr. Sam Whiting had also long since found a new home at Bayer in early August. ...Could very well be a promotional push from the Big Biz boys for their show as @Flyingchef has so eloquently stated, perhaps based on a bit of foreshadowing for events to come. Go Brady!!!

3 · Reply

gscdefense Oct. 4 at 7:20 PM

$TPST One good thing is this stock has retained a relatively high number of watchers on here. Compare that to BURU who had 2.5B shares traded last week for a penny stock and doesn’t have as many as us

0 · Reply

LoUber Oct. 4 at 6:28 PM

$TPST Under Stephen Brady, Tempest has positioned itself as a polished acquisition candidate: the company recently paid off its entire outstanding loan (≈ US$3.5 million), including all accrued interest and exit penalties, fully terminating the debt and releasing all associated liens. At the same time, Tempest has retained MTS Health Partners to drive a formal strategic review and to solicit buyout, merger, or licensing offers. Concurrently, Tempest’s clinical programs (notably TPST‑1120 / amezalpat) have cleared key regulatory milestones with FDA/EMA, secured Orphan Drug and Fast Track designations, and triggered a “Study May Proceed” letter for TPST‑1495 — all moves that materially strengthen its appeal as an acquirable biotech. @Johnquest123 ...Yeah, this is EXACTLY what a "Scam CEO" would do!

2 · Reply

thaboss8854 Oct. 4 at 5:17 PM

$TPST so what are we thinking about the YouTube interview? Are there no active interest or offers so they are trying to tell the parties hey we are still here? With MTS health working on it, that's not likely and this video won't change the outcome. In Brady's words he said he wants to maximize shareholders value. Could it be he is trying to tell us to load up and hold without really giving anything away? Is he trying to bless us with a lot of wealth? Maybe TPST had nothing to do with the video and the channel just happened to post it on their own. Anyways it's up to people's interpretation. I don't fully understand the point of why the video is released because it doesn't give anything away regarding the buyout but nothing has really changed for me. It is still a great product. I am going to pretend it's my second point and keep holding on and get excited.

5 · Reply

Bulltrader988 Oct. 4 at 4:04 PM

$TPST key $11 👃👀 https://finviz.com/quote.ashx?t=TPST&ty=c&ta=1&p=d

0 · Reply

LiquidThetaLEAPS Oct. 4 at 8:15 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $TPST Current Share Price: $10.40 Contracts: $TPST October 17, 2025 $2 Calls Scale in: $0.05- $0.06 Scale out: $0.07-$0.09 Can Easily Capture: 60% ROI Blended DTE: 14 Days | Join Elites here: https://liquidtheta.com/options

0 · Reply

th3_fail_k1ng Oct. 4 at 6:09 AM

$TPST next week all will be revealed. Sword of omens give me sight beyond sight!

0 · Reply

Tempest Reports Second Quarter 2025 Financial Results and Provides Business Update

Jun 30, 2025, 8:00 AM EDT - 3 months ago

Tempest Receives Clearance to Proceed with Pivotal Trial of Amezalpat Combination Therapy for First-Line HCC in China

Jun 11, 2025, 8:00 AM EDT - 4 months ago

Tempest Announces $4.6 Million Registered Direct Offering of Common Stock

Jun 5, 2025, 8:00 AM EDT - 4 months ago

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC

May 13, 2025, 4:28 PM EDT - 5 months ago

Tempest Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 28, 2025, 4:05 PM EDT - 5 months ago

Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 5 months ago

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Apr 9, 2025, 4:30 PM EDT - 6 months ago

Tempest Announces Plan to Explore Strategic Alternatives to Advance Promising Pipeline of Clinical Oncology Assets and Maximize Stockholder Value

Mar 27, 2025, 4:10 PM EDT - 6 months ago

Tempest Reports Year End 2024 Financial Results and Provides Business Update

Mar 25, 2025, 4:30 PM EDT - 6 months ago

Tempest Announces Amezalpat Poster Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Mar 13, 2025, 8:00 AM EDT - 7 months ago

FDA Study May Proceed Notice Received for Phase 2 Trial of TPST-1495 for the Treatment of Familial Adenomatous Polyposis (FAP)

Feb 10, 2025, 8:00 AM EST - 8 months ago

Tempest Granted Fast Track Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma

Feb 7, 2025, 4:30 PM EST - 8 months ago

Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Jan 6, 2025, 8:00 AM EST - 9 months ago

Tempest Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Amezalpat to Treat Patients with Hepatocellular Carcinoma (HCC)

Nov 25, 2024, 4:30 PM EST - 11 months ago

Tempest to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 12, 2024, 4:21 PM EST - 11 months ago

Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update

Oct 10, 2024, 9:06 AM EDT - 1 year ago

Why Is Cancer Focused Tempest Therapeutics Stock Trading Higher On Thursday?

Oct 10, 2024, 7:01 AM EDT - 1 year ago

Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial

Sep 20, 2024, 4:30 PM EDT - 1 year ago

Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 15, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma

Aug 8, 2024, 4:56 PM EDT - 1 year ago

Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update

Jun 20, 2024, 9:43 AM EDT - 1 year ago

What's Going On With Cancer-Focused Tempest Therapeutics Stock On Thursday?

Jun 18, 2024, 6:22 PM EDT - 1 year ago

Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma

May 31, 2024, 3:45 PM EDT - 1 year ago

Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)

May 9, 2024, 4:29 PM EDT - 1 year ago

Tempest Reports First Quarter 2024 Financial Results and Provides Business Update

Apr 17, 2024, 1:26 PM EDT - 1 year ago

Tempest Therapeutics: Multiple 2024 Catalysts Make This A Must Watch

Apr 9, 2024, 8:00 AM EDT - 1 year ago

Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting

Apr 4, 2024, 8:00 AM EDT - 1 year ago

Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications

Mar 19, 2024, 4:25 PM EDT - 1 year ago

Tempest Reports Year End 2023 Financial Results and Provides Business Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting

Nov 20, 2023, 8:00 AM EST - 2 years ago

Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference

Nov 8, 2023, 5:17 PM EST - 2 years ago

Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update

Oct 13, 2023, 4:13 PM EDT - 2 years ago

Tempest Therapeutics shares end wild week with 8% drop

Oct 12, 2023, 12:49 PM EDT - 2 years ago

Tempest Therapeutics shares head back to earth after 4,000% gain

Oct 12, 2023, 11:26 AM EDT - 2 years ago

Top trending biotech stocks: ANVS, MTNB, AVTX, TPST

ANVS AVTX MTNB

Oct 11, 2023, 12:29 PM EDT - 2 years ago

Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise

Oct 11, 2023, 8:01 AM EDT - 2 years ago

Tempest Adopts Limited Duration Stockholder Rights Plan

Oct 11, 2023, 8:00 AM EDT - 2 years ago

Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study

Oct 10, 2023, 4:05 PM EDT - 2 years ago

Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development

Aug 10, 2023, 4:13 PM EDT - 2 years ago

Tempest Reports Second Quarter 2023 Financial Results and Provides Business Update

May 31, 2023, 4:05 PM EDT - 2 years ago

Tempest to Present at the Jefferies Global Healthcare Conference

May 25, 2023, 5:00 PM EDT - 2 years ago

Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers

May 10, 2023, 4:15 PM EDT - 2 years ago

Tempest Reports First Quarter 2023 Financial Results and Provides Business Update

Apr 27, 2023, 4:58 PM EDT - 2 years ago

Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma

Apr 26, 2023, 6:41 PM EDT - 2 years ago

Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

Mar 22, 2023, 5:26 PM EDT - 2 years ago

Tempest Reports Year End 2022 Financial Results and Provides Business Update

Mar 14, 2023, 4:30 PM EDT - 2 years ago

Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting

Nov 22, 2022, 4:05 PM EST - 3 years ago

Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference

gscdefense Oct. 5 at 12:59 AM

$TPST So we just went from 5747 on Webull popularity ranking to 439. There was only one comment today.

1 · Reply

gainsareus Oct. 5 at 12:22 AM

$TPST probably one of the most intelligent boards I’ve seen. Is it because bio requires higher intelligence or you’ll just know where the winners are🤔

1 · Reply

josegodoy Oct. 4 at 11:29 PM

1 · Reply

GreylockSec Oct. 4 at 9:30 PM

3 · Reply

gscdefense Oct. 4 at 7:20 PM

0 · Reply

LoUber Oct. 4 at 6:28 PM

2 · Reply

thaboss8854 Oct. 4 at 5:17 PM

5 · Reply

Bulltrader988 Oct. 4 at 4:04 PM

$TPST key $11 👃👀 https://finviz.com/quote.ashx?t=TPST&ty=c&ta=1&p=d

0 · Reply

LiquidThetaLEAPS Oct. 4 at 8:15 AM

0 · Reply

th3_fail_k1ng Oct. 4 at 6:09 AM

$TPST next week all will be revealed. Sword of omens give me sight beyond sight!

0 · Reply

Johnquest123 Oct. 4 at 4:50 AM

$TPST lol nothing came out of mts partners so they released self funded video bs as last measure. Scam CEO

1 · Reply

moselbh1 Oct. 4 at 2:15 AM

$TPST I don’t believe the interview with Brady and others was recent simply because they are not employees anymore and the way they referred to the company . For example Brady says they are a wet lab but that hasn’t been true for a couple of months. Even though I think that it’s old I really liked the addition information and still came away this could be bigger than I anticipate. The global interest in oncologists wanting to be a part of the study stood out to me. Brady commented that he had never seen such interest. My biggest question is why did the video drop now. Producers usually want the latest news but this is a little old and employees aren’t there. Interesting to say the least and I’m not sure if it’s good or bad.

4 · Reply

MindsEye66 Oct. 4 at 1:40 AM

$TPST Interview completed 9/15 and dropped just yesterday? Timing timing!

0 · Reply

caugiii Oct. 4 at 1:02 AM

$TPST We recently presented our strategic alternatives and shared these outcomes at the HCC society meeting, where the results drew strong interest. The discussion even led to enthusiasm for expanding into renal cancer studies, underscoring the broader potential impact of these programs.

0 · Reply

caugiii Oct. 4 at 1:02 AM

$TPST https://youtu.be/ltUKDJdjBRg Interviewed on 9/15. They definitely see it as a Quiet Period. Everyone's interested in this drug, and it's also a game changer in oncology. I think maybe there's going to be a much bigger buyout than we expected. Maybe it's going to be more than 35B dollars. The compound 1120 does not directly attack cancer cells but instead blocks cellular lipid metabolism, making existing anticancer drugs work more effectively. It is a groundbreaking therapy, recognized as such even by the FDA. In a collaborative clinical trial with Roche, 1120 extended overall survival from 15 months to 21 months—an impressive six-month improvement. Moreover, response rates increased significantly, from 12% to 30%. Clearly, 1120 is a remarkable drug. Meanwhile, 1495 is also focused on colorectal cancer, but it is being developed with the potential to serve as a preventive therapy—another exciting advancement.

3 · Reply

holmesriley Oct. 3 at 11:54 PM

$TPST Brady has been on this show before, he talks the first few minutes then it shows a video about the company, then the last couple of minutes he talks more about 1120 and 1495 https://youtu.be/ltUKDJdjBRg?si=TAhhvg6OMYRUAEMM

8 · Reply